BioAge Labs (NASDAQ:BIOA) Shares Down 6.1% on Insider Selling

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price traded down 6.1% on Friday following insider selling activity. The company traded as low as $19.72 and last traded at $20.1950. 402,854 shares were traded during trading, a decline of 63% from the average session volume of 1,076,016 shares. The stock had previously closed at $21.51.

Specifically, CEO Kristen Fortney sold 233,107 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer owned 976,949 shares in the company, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Citigroup lifted their price target on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Down 7.2%

The stock has a fifty day moving average of $11.96 and a 200-day moving average of $7.53. The stock has a market capitalization of $715.57 million, a PE ratio of -13.15 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Hedge Funds Weigh In On BioAge Labs

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC lifted its holdings in shares of BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after purchasing an additional 270,479 shares during the last quarter. Marshall Wace LLP grew its position in shares of BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after acquiring an additional 173,388 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the period. Stonepine Capital Management LLC raised its position in BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.